Enzon and Viskase Enter into Merger Agreement

Enzon Pharmaceuticals and Viskase Companies have entered into a definitive all-stock merger agreement, with Viskase merging into an Enzon subsidiary and the combined entity operating as Viskase Holdings, Inc. under the leadership of Viskase's current CEO, Timothy P. Feast. Upon closing, assuming full exchange of Enzon's Series C Preferred Stock, Enzon's existing common stockholders are expected to own approximately 2.06%, Series C Preferred holders 13.84%, and Viskase stockholders 84.1% of the combined company, subject to adjustments; the deal is pending stockholder and regulatory approvals.

Analysis

Enzon Pharmaceuticals (ENZN) and Viskase Companies (VKSC) have entered into a definitive all-stock merger agreement that functions as a reverse merger, with the private operating company Viskase set to become public by merging into an Enzon subsidiary. The resulting entity, Viskase Holdings, Inc., will be led by Viskase's current CEO, Timothy P. Feast, and will be dominated by Viskase's existing shareholders, who are expected to own approximately 84.1% of the combined company. This transaction marks the culmination of Enzon's strategy as a 'public company acquisition vehicle' but results in severe dilution for its common stockholders, who will be left with only about 2.06% ownership. The deal's structure was facilitated by key stakeholders, including Icahn Enterprises (IEH), whose holdings of Series C Preferred Stock will be converted into approximately 13.84% of the new entity. The merger fundamentally pivots the company's focus from pharmaceuticals to Viskase's core business of producing casings for the processed meat industry, effectively providing Viskase with a public listing on the OTCQX market.

Key Decisions for Investors

• Existing Enzon common stockholders must recognize the significant dilution from this transaction, as their ownership will be reduced to approximately 2.06%, making the value of their holdings almost entirely dependent on the market's valuation of the Viskase business.
• Investors should evaluate the new combined entity based on the fundamentals, growth prospects, and competitive landscape of Viskase's industrial food-casing business, as Enzon's historical operations and legacy as a pharmaceutical company are now irrelevant to future performance.
• For Viskase shareholders, the merger provides a path to public market liquidity, but they should monitor the closing conditions, including regulatory and shareholder approvals, and the post-merger performance of the stock on the OTCQX market.